Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS Research and Therapy
Published in: AIDS Research and Therapy 1/2010

Open Access 01-12-2010 | Research

Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization

Authors: Mohammad-Ali Jenabian, Héla Saïdi, Charlotte Charpentier, Hicham Bouhlal, Dominique Schols, Jan Balzarini, Thomas W Bell, Guido Vanham, Laurent Bélec

Published in: AIDS Research and Therapy | Issue 1/2010

Login to get access

Abstract

Background

HIV-1 in genital secretions may be opsonized by several molecules including complement components. Opsonized HIV-1 by complement enhances the infection of various mucosal target cells, such as dendritic cells (DC) and epithelial cells.

Results

We herein evaluated the effect of HIV-1 complement opsonization on microbicide candidates' activity, by using three in vitro mucosal models: CCR5-tropic HIV-1JR-CSF transcytosis through epithelial cells, HIV-1JR-CSF attachment on immature monocyte-derived dendritic cells (iMDDC), and infectivity of iMDDC by CCR5-tropic HIV-1BaL and CXCR4-tropic HIV-1NDK. A panel of 10 microbicide candidates [T20, CADA, lectines HHA & GNA, PVAS, human lactoferrin, and monoclonal antibodies IgG1B12, 12G5, 2G12 and 2F5], were investigated using cell-free unopsonized or opsonized HIV-1 by complements. Only HHA and PVAS were able to inhibit HIV trancytosis. Upon opsonization, transcytosis was affected only by HHA, HIV-1 adsorption on iMDDC by four molecules (lactoferrin, IgG1B12, IgG2G5, IgG2G12), and replication in iMDDC of HIV-1BaL by five molecules (lactoferrin, CADA, T20, IgG1B12, IgG2F5) and of HIV-1NDK by two molecules (lactoferrin, IgG12G5).

Conclusion

These observations demonstrate that HIV-1 opsonization by complements may modulate in vitro the efficiency of candidate microbicides to inhibit HIV-1 infection of mucosal target cells, as well as its crossing through mucosa.
Literature
1.
Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W: SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PloS one. 2008, 3 (1): e1474- 10.1371/journal.pone.0001474PubMedCentralCrossRefPubMed
2.
Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. The New England journal of medicine. 2008, 359 (5): 463-472. 10.1056/NEJMoa0707957CrossRefPubMed
3.
Saidi H, Jenabian MA, Bélec L: Early events in vaginal HIV transmission: Implications in microbicide development. Future Virol. 2009, 4 (3): 259-269. 10.2217/fvl.09.10.CrossRef
4.
Ying H, Ji X, Hart ML, Gupta K, Saifuddin M, Zariffard MR, Spear GT: Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS research and human retroviruses. 2004, 20 (3): 327-335. 10.1089/088922204322996563CrossRefPubMed
5.
Royce RA, Sena A, Cates W, Cohen MS: Sexual transmission of HIV. The New England journal of medicine. 1997, 336 (15): 1072-1078. 10.1056/NEJM199704103361507CrossRefPubMed
6.
Shepard RN, Schock J, Robertson K, Shugars DC, Dyer J, Vernazza P, Hall C, Cohen MS, Fiscus SA: Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments. Journal of clinical microbiology. 2000, 38 (4): 1414-1418.PubMedCentralPubMed
7.
Neurath AR, Strick N, Li YY: Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides. BMC infectious diseases. 2006, 6: 150- 10.1186/1471-2334-6-150PubMedCentralCrossRefPubMed
8.
Stoiber H, Speth C, Dierich MP: Role of complement in the control of HIV dynamics and pathogenesis. Vaccine. 2003, 21 (Suppl 2): S77-82. 10.1016/S0264-410X(03)00203-2CrossRefPubMed
9.
Rahimi A, Sepehri H, Pakravesh J, Bahar K: Quantification of C3 and C4 in infertile men with antisperm antibody in their seminal plasma. Am J Reprod Immunol. 1999, 41 (5): 330-336.CrossRefPubMed
10.
Stoiber H, Banki Z, Wilflingseder D, Dierich MP: Complement-HIV interactions during all steps of viral pathogenesis. Vaccine. 2008, 26 (24): 3046-3054. 10.1016/j.vaccine.2007.12.003CrossRefPubMed
11.
Vanderpuye OA, Labarrere CA, McIntyre JA: The complement system in human reproduction. Am J Reprod Immunol. 1992, 27 (3-4): 145-155.CrossRefPubMed
12.
Bouhlal H, Chomont N, Haeffner-Cavaillon N, Kazatchkine MD, Belec L, Hocini H: Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol. 2002, 169 (6): 3301-3306.CrossRefPubMed
13.
Bouhlal H, Chomont N, Requena M, Nasreddine N, Saidi H, Legoff J, Kazatchkine MD, Belec L, Hocini H: Opsonization of HIV with complement enhances infection of dendritic cells and viral transfer to CD4 T cells in a CR3 and DC-SIGN-dependent manner. J Immunol. 2007, 178 (2): 1086-1095.CrossRefPubMed
14.
Saidi H, Eslahpazir J, Carbonneil C, Carthagena L, Requena M, Nassreddine N, Belec L: Differential modulation of human lactoferrin activity against both R5 and X4-HIV-1 adsorption on epithelial cells and dendritic cells by natural antibodies. J Immunol. 2006, 177 (8): 5540-5549.CrossRefPubMed
15.
Ball JM, Moldoveanu Z, Melsen LR, Kozlowski PA, Jackson S, Mulligan MJ, Mestecky JF, Compans RW: A polarized human endometrial cell line that binds and transports polymeric IgA. In vitro cellular & developmental biology. 1995, 31 (3): 196-206.CrossRef
16.
Van Damme EJAA, Peumans WJ: Related mannose-specific lectins from different species of the family Amaryllidaceae. Physiol Plant. 1988, 73: 52-57. 10.1111/j.1399-3054.1988.tb09192.x.CrossRef
17.
Baba M, Schols D, De Clercq E, Pauwels R, Nagy M, Gyorgyi-Edelenyi J, Low M, Gorog S: Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation. Antimicrobial agents and chemotherapy. 1990, 34 (1): 134-138.PubMedCentralCrossRefPubMed
18.
Berkhout B, Floris R, Recio I, Visser S: The antiviral activity of the milk protein lactoferrin against the human immunodeficiency virus type 1. Biometals. 2004, 17 (3): 291-294. 10.1023/B:BIOM.0000027707.82911.beCrossRefPubMed
19.
Vermeire K, Brouwers J, Van Herrewege Y, Le Grand R, Vanham G, Augustijns P, Bell TW, Schols D: CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Current HIV research. 2008, 6 (3): 246-256. 10.2174/157016208784324958CrossRefPubMed
20.
Bouhlal H, Galon J, Kazatchkine MD, Fridman WH, Sautes-Fridman C, Haeffner Cavaillon N: Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. J Immunol. 2001, 166 (5): 3377-3383.CrossRefPubMed
21.
Hocini H, Becquart P, Bouhlal H, Chomont N, Ancuta P, Kazatchkine MD, Belec L: Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells. Journal of virology. 2001, 75 (11): 5370-5374. 10.1128/JVI.75.11.5370-5374.2001PubMedCentralCrossRefPubMed
22.
Stoiber H, Frank I, Spruth M, Schwendinger M, Mullauer B, Windisch JM, Schneider R, Katinger H, Ando I, Dierich MP: Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry?. Molecular immunology. 1997, 34 (12-13): 855-863. 10.1016/S0161-5890(97)00108-9CrossRefPubMed
23.
Thieblemont N, Delibrias C, Fischer E, Weiss L, Kazatchkine MD, Haeffner-Cavaillon N: Complement enhancement of HIV infection is mediated by complement receptors. Immunopharmacology. 1993, 25 (2): 87-93. 10.1016/0162-3109(93)90012-FCrossRefPubMed
24.
Banki Z, Stoiber H, Dierich MP: HIV and human complement: inefficient virolysis and effective adherence. Immunology letters. 2005, 97 (2): 209-214. 10.1016/j.imlet.2004.11.007CrossRefPubMed
25.
Pinter C, Siccardi AG, Lopalco L, Longhi R, Clivio A: HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology. AIDS research and human retroviruses. 1995, 11 (8): 971-980. 10.1089/aid.1995.11.971CrossRefPubMed
26.
Schmitz J, Zimmer JP, Kluxen B, Aries S, Bogel M, Gigli I, Schmitz H: Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. The Journal of clinical investigation. 1995, 96 (3): 1520-1526. 10.1172/JCI118190PubMedCentralCrossRefPubMed
27.
Stoiber H, Ammann C, Spruth M, Mullauer B, Eberhart A, Harris CL, Huber CG, Longhi R, Falkensammer B, Wurzner R: Enhancement of complement-mediated lysis by a peptide derived from SCR 13 of complement factor H. Immunobiology. 2001, 203 (4): 670-686.CrossRefPubMed
28.
Stoiber H, Pinter C, Siccardi AG, Clivio A, Dierich MP: Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). The Journal of experimental medicine. 1996, 183 (1): 307-310. 10.1084/jem.183.1.307CrossRefPubMed
29.
Takefman DM, Sullivan BL, Sha BE, Spear GT: >Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. Virology. 1998, 246 (2): 370-378. 10.1006/viro.1998.9205CrossRefPubMed
30.
Stone A: Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nature reviews. 2002, 1 (12): 977-985. 10.1038/nrd959PubMed
31.
Balzarini J: Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol. 2007, 5 (8): 583-597. 10.1038/nrmicro1707CrossRefPubMed
32.
Balzarini J, Hatse S, Vermeire K, Princen K, Aquaro S, Perno CF, De Clercq E, Egberink H, Vanden Mooter G, Peumans W: Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrobial agents and chemotherapy. 2004, 48 (10): 3858-3870. 10.1128/AAC.48.10.3858-3870.2004PubMedCentralCrossRefPubMed
33.
Saidi H, Magri G, Nasreddine N, Requena M, Belec L: R5- and X4-HIV-1 use differentially the endometrial epithelial cells HEC-1A to ensure their own spread: implication for mechanisms of sexual transmission. Virology. 2007, 358 (1): 55-68. 10.1016/j.virol.2006.07.029CrossRefPubMed
34.
Vives RR, Imberty A, Sattentau QJ, Lortat-Jacob H: Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. The Journal of biological chemistry. 2005, 280 (22): 21353-21357. 10.1074/jbc.M500911200CrossRefPubMed
35.
June RA, Schade SZ, Bankowski MJ, Kuhns M, McNamara A, Lint TF, Landay AL, Spear GT: Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS (London, England). 1991, 5 (3): 269-274.CrossRef
36.
Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000, 100 (5): 587-597. 10.1016/S0092-8674(00)80694-7CrossRefPubMed
37.
Requena M, Bouhlal H, Nasreddine N, Saidi H, Gody JC, Aubry S, Gresenguet G, Kazatchkine MD, Sekaly RP, Belec L: Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins. Immunology. 2008, 123 (4): 508-518. 10.1111/j.1365-2567.2007.02717.xPubMedCentralCrossRefPubMed
38.
Saidi H, Magri G, Carbonneil C, Nasreddine N, Requena M, Belec L: >IFN-gamma-activated monocytes weakly produce HIV-1 but induce the recruitment of HIV-sensitive T cells and enhance the viral production by these recruited T cells. Journal of leukocyte biology. 2007, 81 (3): 642-653. 10.1189/jlb.0406278CrossRefPubMed
39.
Legrand D, Vigie K, Said EA, Elass E, Masson M, Slomianny MC, Carpentier M, Briand JP, Mazurier J, Hovanessian AG: Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. European journal of biochemistry/FEBS. 2004, 271 (2): 303-317. 10.1046/j.1432-1033.2003.03929.xCrossRefPubMed
40.
Nisole S, Said EA, Mische C, Prevost MC, Krust B, Bouvet P, Bianco A, Briand JP, Hovanessian AG: The anti-HIV pentameric pseudopeptide HB-19 binds the C-terminal end of nucleolin and prevents anchorage of virus particles in the plasma membrane of target cells. The Journal of biological chemistry. 2002, 277 (23): 20877-20886. 10.1074/jbc.M110024200CrossRefPubMed
41.
Margolis L, Shattock R: Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?. Nat Rev Microbiol. 2006, 4 (4): 312-317. 10.1038/nrmicro1387CrossRefPubMed
Metadata
Title
Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization
Authors
Mohammad-Ali Jenabian
Héla Saïdi
Charlotte Charpentier
Hicham Bouhlal
Dominique Schols
Jan Balzarini
Thomas W Bell
Guido Vanham
Laurent Bélec
Publication date
01-12-2010
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2010
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/1742-6405-7-16

Other articles of this Issue 1/2010

AIDS Research and Therapy 1/2010 Go to the issue

Research

Reduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: a retrospective observational study

Short report

Specific eradication of HIV-1 from infected cultured cells

Research

The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients

Research

Experiences in conducting multiple community-based HIV prevention trials among women in KwaZulu-Natal, South Africa

Review

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection

Research

Nef-specific CD45RA+ CD8+ T cells secreting MIP-1β but not IFN-γ are associated with nonprogressive HIV-1 infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits